Изменение показателей системы крови человека у больных COVID-19

   Как известно, вирус SARS-CoV-2 влияет практически на все системы, органы и ткани человека, вызывая их поражение в большей или меньшей степени. Наблюдение за пациентами, перенесшими COVID-19, во всем мире указывает на значительные изменения, происходящие в системе кроветворения и морфологии клеток крови. Настоящий обзор посвящен анализу литературных данных о влиянии вируса SARS-CoV-2 на изменения показателей системы крови человека, что имеет важное значение в практической работе всех специалистов здравоохранения.

1. Wenzhong L., Hualan L. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. Biological and Medicinal Chemistry. 2020 Mar; v5:38 Preprint. doi.:10.26434/chemrxiv. 11938173.

2. Ehsani S. COVID-19 and iron dysregulation: distant sequence similarity between hepcidin and the novel coronavirus spike glycoprotein. Biology Direct. 2020;15 (19):1-13. Doi:10.1186/s13062-020-00275-2

3. Hirschhorn T, Stockwell BR. The development of the concept of ferroptosis. Free Radic Biol Med 2019 Mar; 133: 130-143. doi: 10.1016/j.freeradbiomed.2018.09.043.

4. Евтюгина Н.Г., Санникова С.С., Пешкова А.Д. и др. Количественные и качественные изменения клеток крови при COVID-19. Казанский мед. ж. 2021; 102 (2): 141–155. DOI: 10.17816/KMJ2021-141.

5. Zhao J., Yang Y., Huang H. et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. Clinical Infectious Diseases 2021;.73(2):328-331, doi: 10.1093/cid/ciaa1150

6. Задумина Д.Н., Скворцов В.В. Изменение гематологических показателей при COVID-19. Лечащий Врач. 2022; 11(25): 30-36. DOI: 10.51793/OS.2022.25.11.005.

7. Liu Y, Sun W, Guo Y, et al. Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study. Platelets. 2020 May 18; 31(4): 490-496. doi: 10.1080/09537104.2020.1754383.

8. Zhang Y, Zeng X, Jiao Y, et al. Mechanisms involved in the development of thrombocytopenia in patients with COVID-19. Thromb Res. 2020 Sep; 193: 110-115. doi: 10.1016/j.thromres.2020.06.008.

9. Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30; 382(18): 1708-1720. doi: 10.1056/NEJMoa2002032.

10. Yang X, Yang Q, Wang Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J ThrombHaemost. 2020 Jun; 18(6): 1469-1472. doi: 10.1111/jth.14848. Epub 2020 May 4. PMID: 32302435.

11. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020 Jun; 7(6): e438-e440. doi: 10.1016/S2352-3026(20)30145-9. Epub 2020 May 11. PMID: 32407672; PMCID: PMC7213964.

12. Thachil J. What do monitor platelet counts in COVID-19 teach us? J Thromb Haemost. 2020 Aug;18(8): 2071-2072. doi: 10.1111/jth.14879.

13. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. ClinChimActa.2020 Jul; 506: 145-148. doi: 10.1016/j.cca.2020.03.022.

14. Henry BM, de Oliveira MHS, Benoit S, Plebani M, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020 Jun 25; 58(7): 1021-1028. doi: 10.1515/cclm-2020-0369.

15. Bomhof G, Mutsaers PGNJ, Leebeek FWG, et al. COVID-19-associated immune thrombocytopenia. Br J Haematol. 2020 Jul; 190(2): e61-e64. doi: 10.1111/bjh.16850.

16. Chabert A, Hamzeh-Cognasse H, Pozzetto B, et al. Human platelets and their capacity of binding viruses: meaning and challenges? BMC Immunol.2015 Apr 28; 16: 26. doi: 10.1186/s12865-015-0092-1.

17. Assinger A. Platelets and infection — an emerging role of platelets in viral infection.. Frontiers in immunology. 2014, Dec 18; vol. 5: 649. doi: 10.3389/fimmu.2014.00649

18. Seyoum M, Enawgaw B, Melku M. Human blood platelets and viruses: defense mechanism and role in the removal of viral pathogens. Thromb J. 2018 Jul 17; 16: 16. doi: 10.1186/s12959-018-0170-8.

19. Lador A, Leshem-Lev D, Spectre G, et al. Characterization of surface antigens of reticulated immature platelets. J Thromb Thrombolysis. 2017 Oct; 44(3): 291-297. doi: 10.1007/s11239-017-1533-x.

20. Handtke S, Steil L, Palankar R, et al. Role of Platelet Size Revisited-Function and Protein Composition of Large and Small Platelets. ThrombHaemost. 2019 Mar; 119(3): 407-420. doi: 10.1055/s-0039-1677875.

21. Hille L, Lenz M, Vlachos A, et al. Ultrastructural, transcriptional, and functional differences between human reticulated and non-reticulated platelets. J ThrombHaemost. 2020 Aug; 18(8): 2034-2046. doi: 10.1111/jth.14895.

22. Handtke S, Thiele T. Large and small platelets-(When) do they differ? J ThrombHaemost. 2020 Jun; 18(6): 1256-1267. doi: 10.1111/jth.14788.

23. Zhang S, Liu Y, Wang X, et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J HematolOncol. 2020 Sep 4; 13(1): 120. doi: 10.1186/s13045-020-00954-7.

24. Hottz ED, Azevedo-Quintanilha IG, Palhinha L, et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020 Sep 10; 136(11): 1330-1341. doi: 10.1182/blood.2020007252.

25. Manne BK, Denorme F, Middleton EA, et al. Platelet gene expression and function in patients with COVID-19. Blood. 2020 Sep 10; 136(11): 1317-1329. doi: 10.1182/blood.2020007214.

26. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation.Blood. 2020 Jun 4; 135(23): 2033-2040. doi: 10.1182/blood.2020006000.

27. Spyropoulos AC, Levy JH, Ageno W, et al; Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J ThrombHaemost. 2020 Aug; 18(8): 1859-1865. doi: 10.1111/jth.14929.

28. Helms J, Tacquard C, Severac F, et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020 Jun; 46(6): 1089-1098. doi: 10.1007/s00134-020-06062-x.

29. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020 Jun 25; 58(7): 1116-1120. doi: 10.1515/cclm-2020-0188.

30. Li, Q., Cao, Y., Chen, L. et al. Hematological features of persons with COVID-19. Leukemia. 2020.34:2163–2172 doi:10.1038/s41375-020-0910-1

31. Thachil J, Cushman M, Srivastava A. A proposal for staging COVID-19 coagulopathy.Res PractThrombHaemost. 2020; 4(5): 731-736. Published 2020 Jul 6. doi: 10.1002/rth2.12372

32. Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020 Jun; 190: 62. doi: 10.1016/j.thromres.2020.04.014.

33. Othman M, Labelle A, Mazzetti I, et al. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood. 2007 Apr 1; 109(7): 2832-9. doi: 10.1182/blood-2006-06-032524. PMID: 17148587.

34. Escher R, Breakey N, Lämmle B. ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients. Thromb Res. 2020 Aug; 192: 174-175. doi: 10.1016/j.thromres.2020.05.032.

35. Martinelli N, Montagnana M, Pizzolo F, et al. A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19. Thromb Res. 2020 Sep; 193: 170-172. doi: 10.1016/j.thromres.2020.07.034.

36. Blasi A, von Meijenfeldt FA, Adelmeijer J, et al. In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation. J ThrombHaemost. 2020 Oct; 18(10): 2646-2653. doi: 10.1111/jth.15043.

37. O. Otto, P. Rosendahl, et al., J. Guck Real-time deformability cytometry: on-the-fly cell mechanical phenotyping/ Nature Methods, 2015, 12: 199-202 doi: 10.1038/nmeth.3281.

38. Kubánková M, Hohberger B, Hoffmanns J, et al. Physical phenotype of blood cells is altered in COVID-19. Biophys J. 2021 Jul 20; 120(14): 2838-2847. doi: 10.1016/j.bpj.2021.05.025.

39. Kaur G, Sandeep F, Olayinka O, et al. Morphologic Changes in Circulating Blood Cells of COVID-19 Patients. Cureus. 2021 Feb 18; 13(2): 13416. doi: 10.7759/cureus.13416. PMID: 33758711; PMCID: PMC7978157

40. Багненко, С. Ф., Рассохин, В. В., Трофимова и др. Эволюция пандемии COVID-19. Балтийский медицинский образовательный центр. 2021. 410 с.

41. Министерство здравоохранения Российской Федерации. Временные методические рекомендации: Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). 2022. Версия 16 : 249 с.

42. Садретдинов М.А., Тимербулатов Ш.В., Валишин Д.А., и др. Диагностика COVID-19: неиспользованные технологии — возможности общего анализа крови. Медицинский вестник Башкортостана. 2020. Т. 15, № 3(87). С. 31-34.

43. Тимофеева Н.Ю., Кострова О.Ю., Стоменская И.С., и др. Изменения показателей общего анализа крови и коагулограммы при легком течении коронавирусной инфекции. Евразийский мед. журнал. 2021. № 2. С. 44-49.. DOI: 10.47026/2413-4864-2021-2-44-49.

44. Губенко Н.С., Будко А.А., Плисюк А.Г. и др. Связь показателей общего анализа крови с тяжестью течения COVID-19 у госпитализированных пациентов. Южно-Российский журнал терапевтической практики. 2021; 2(1): 90-101. doi.10.21886/2712-8156-2021-2-1-90-101.